Congressional Lupus Caucus Petitions FDA Re Quinacrine

The Congressional Lupus Caucus wrote the U.S. Food and Drug Administration in response to lupus patients worried that a current review by the FDA could determine that the active ingredient in quinacrine, a drug often used to treat lupus patients, will not continue to be available to pharmacies. “As Co-chairs of the Congressional Lupus Caucus, we share their concerns regarding the adverse impact of a decision by the FDA to restrict access to quinacrine, which for over fifty years has been a critical treatment for numerous symptoms of lupus and other autoimmune diseases.”
 
Click here for the letter to the FDA’s Center for Drug Evaluation and Research